US2015313926A1PendingUtilityA1

Syn3 compositions and methods

45
Assignee: MERCK SHARP & DOHMEPriority: Dec 20, 2001Filed: Jul 13, 2015Published: Nov 5, 2015
Est. expiryDec 20, 2021(expired)· nominal 20-yr term from priority
Inventors:Peter M. IhnatLeonore C. Witchey-LakshmananVarda SandweissSydney Ugwu
A61P 35/00A61P 43/00A61P 13/10A61K 9/0019A61K 38/212A61K 48/0008A61K 31/70A61K 48/00C12N 2710/10343C12N 15/86A61K 47/12A61K 47/18A61K 47/26A61K 31/7028A61K 31/704C12N 2710/10351A61K 47/10C07J 41/0061A61K 9/19
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are aqueous and nonaqueous solution formulations containing agents that are useful for treating cancer.

Claims

exact text as granted — not AI-modified
1 - 19 . (canceled) 
     
     
         20 . A pharmaceutical composition comprising SYN3, hydroxypropyl-beta-cyclodextrin, a polysorbate, and a citrate buffer. 
     
     
         21 . The pharmaceutical composition of  claim 20 , comprising the SYN3 at a concentration of about 0.001 mg/ml to about 150 mg/ml. 
     
     
         22 . The pharmaceutical composition of  claim 20 , wherein the polysorbate is Polysorbate 20 or Polysorbate 80. 
     
     
         23 . The pharmaceutical composition of  claim 20 , comprising the polysorbate at a concentration of about 1 mg/ml to about 36 mg/ml. 
     
     
         24 . The pharmaceutical composition of  claim 20 , comprising the hydroxypropyl-beta-cyclodextrin at a concentration of about 50 mg/ml to about 500 mg/ml. 
     
     
         25 . The pharmaceutical composition of  claim 20 , wherein the citrate buffer is citric acid monohydrate, sodium citrate dehydrate, or a combination thereof. 
     
     
         26 . The pharmaceutical composition of  claim 20  having a pH of about 5 to about 6. 
     
     
         27 . The pharmaceutical composition of  claim 20 , further comprising an antioxidant. 
     
     
         28 . The pharmaceutical composition of  claim 27 , wherein the antioxidant is ascorbic acid. 
     
     
         29 . The pharmaceutical composition of  claim 20 , wherein the composition is lyophilized. 
     
     
         30 . The pharmaceutical composition of  claim 29 , wherein the lyophilized composition further comprises a freeze-drying bulking agent. 
     
     
         31 . The pharmaceutical composition of  claim 30 , wherein the freeze-drying bulking agent is mannitol or glycine. 
     
     
         32 . The pharmaceutical composition of  claim 20 , further comprising a recombinant viral vector encoding an interferon α. 
     
     
         33 . The pharmaceutical composition of  claim 32 , wherein the recombinant viral vector is a recombinant adenoviral vector. 
     
     
         34 . The pharmaceutical composition of  claim 32 , wherein the interferon α is interferon α2b. 
     
     
         35 . The pharmaceutical composition of  claim 32  having a pH of about 7 to about 8.5.

Join the waitlist — get patent alerts

Track US2015313926A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.